Trial Profile
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 06 May 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Final results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 09 Oct 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2019.